What's Happening?
Cambridge-based biotech company STORM Therapeutics has raised $56 million in a Series C funding round to advance its RNA-targeting cancer drug, STC-15, into Phase 2 clinical trials. The funding, supported by existing investors such as Pfizer Ventures
and M Ventures, will facilitate the development of STC-15, the first RNA-modifying enzyme inhibitor to reach human trials. The drug targets METTL3, an enzyme involved in cancer cell differentiation, and has shown promising results in Phase 1 trials with durable tumor regression in sarcoma patients. The Phase 2 trial aims to support accelerated regulatory approval and expand clinical development into other oncology indications.
Why It's Important?
STORM Therapeutics' progress in developing STC-15 represents a significant advancement in cancer treatment, particularly for sarcomas, which are challenging to treat due to their lack of driver mutations. The successful funding round underscores investor confidence in the potential of RNA-targeting therapies to address unmet medical needs. If successful, STC-15 could offer a new therapeutic option for patients with sarcomas and potentially other cancers, improving outcomes and expanding treatment possibilities. The development also highlights the growing interest in RNA-based therapies as a frontier in oncology, with implications for future research and investment in the biotech sector.
What's Next?
With the first patient dosed in the Phase 2 trial, STORM Therapeutics will focus on gathering data to support regulatory approval and further clinical development. The company is also conducting a Phase 1b/2 combination study with a PD-1 inhibitor, exploring the potential of STC-15 in other cancer types. The results of these trials will be closely watched by the medical community and investors, as they could pave the way for new treatment paradigms in oncology. Continued success in clinical trials may attract additional funding and partnerships, further advancing the company's mission to innovate cancer therapies.
